Table 96-2. Results of Initial Treatment with Cisplatin-Based Combination Chemotherapy in Nonseminomatous Mediastinal Germ Cell Tumors

Table 96-2.  Results of Initial Treatment with Cisplatin-Based Combination Chemotherapy in Nonseminomatous Mediastinal Germ Cell Tumors

Author, Year	Number of Evaluable Patients	Chemotherapy Regimen	Number of Complete Responders (%)	Number of Long- Term (> 24 months) Disease-Free Survivors (%)
Funes, 198177	13	PVB	6 (46%)	5 (38%)
Hainsworth, 198232	12	PVB ± A	7 (58%)	7 (58%)
Logothetis, 198533,34	11	CISCA II	NA	4 (36%)
		CISCA/VBIV
Israel, 198533	11*	VAB-6	NA	4 (36%)
Kay, 198736	11	PVB, BEP	7 (64%)	5 (45%)
Nichols, 199017	31	PVB ± A, BEP	18 (58%)	13 (42%)
Bukowski, 199364	16	PVB/EBAP	9 (56%)	9 (56%)
Delgado, 199365	40	VAB-6, PVB, BEP	15 (38%)	14 (35%)
Gerl, 199668	12	PVB, BEP, ECBC	8 (67%)	6 (50%)
Fizazi, 199877	29	VAP-6, PveVB, PVB, BEP	19 (60%)	10 (34%)
Total	186		89 (54%)	73 (39%)

A = Adriamycin; BEP = bleomycin 30 units weekly, etoposide 100 mg/m2 IV × 5 days, cisplatin 20 mg/m2 IV × 5 days, cycles repeated q 3 weeks; CISCAII, CISCA/VBIV = multidrug regimens developed at M.D. Anderson; EBAP = etoposide, bleomycin, doxorubicin, cisplatin; ECBC = etoposide, cisplatin, bleomycin, cyclophosphamide; NA = not available; PVB = cisplatin 20 mg/m2 IV × 5 days, vinblastine 0.15 mg/kg D1, 2, bleomycin 30 U weekly; PveVB = cisplatin, etoposide, vinblastine, bleomycin;  VAB-6 = multidrug regimen developed at Sloan-Kettering.

* Includes patients with retroperitoneal tumors.